Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 162

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

NRAS-mutant melanoma: current challenges and future prospect

Open access
Muñoz-Couselo, Eva, Zamora Adelantado, Ester, Ortiz Vélez, Carolina, Soberino-García, Jesus, Perez-Garcia, Jose Manuel · 2017 · OncoTargets and Therapy

Abstract

Melanoma is one of the most common cutaneous cancers worldwide. Activating mutations in RAS oncogenes are found in a third of all human cancers and NRAS mutations are found in 15%–20% of melanomas. The NRAS -mutant subset of melanoma is more aggressive and associated with poorer outcomes, compared to non- NRAS -mutant melanoma. Although immune checkpoint inhibitors and targeted therapies for BRAF -mutant melanoma are transforming the treatment of metastatic melanoma, the ideal treatment for NRAS -mutant melanoma remains unknown. Despite promising preclinical data, current therapies for NRAS -mutant melanoma remain limited, showing a modest increase in progression-free survival but without any benefit in overall survival. Combining MEK inhibitors with agents inhibiting cell cycling and the PI3K–AKT pathway appears to provide additional benefit; in particular, a strategy of MEK inhibition and CDK4/6 inhibition is likely to be a viable treatment option in the future. Patients whose tumors had NRAS mutations had better response to immunotherapy and better outcomes than patients whose tumors had other genetic subtypes, suggesting that immune therapies – especially immune checkpoint inhibitors – may be particularly effective as treatment options for NRAS -mutant melanoma. Improved understanding of NRAS -mutant melanoma will be essential to develop new treatment strategies for this subset of patients with melanoma. Keywords: metastatic melanoma, NRAS mutation, MEK inhibitor, immunotherapy, trametinib, binimetinib

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/ott.s117121

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

Metadata

Authors
Muñoz-Couselo, E., Zamora Adelantado, E., Ortiz Vélez, C., Soberino-García, J., & Perez-Garcia, J. M.
Venue
OncoTargets and Therapy
Published
2017-08
Volume
Volume 10
Pages
3941-3947
ISSN
1178-6930 (ISSN-L)
OpenAlex
W2743762084
Cited by
162
References
8
FWCI
5.73
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.